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Abstract
Background: The use of small interfering RNA (siRNA) molecules in animals to achieve double-
stranded RNA-mediated interference (RNAi) has recently emerged as a powerful method of
sequence-specific gene knockdown. As DNA-based expression of short hairpin RNA (shRNA) for
RNAi may offer some advantages over chemical and in vitro synthesised siRNA, a number of vectors
for expression of shRNA have been developed. These often feature polymerase III (pol. III)
promoters of either mouse or human origin.
Results: To develop a shRNA expression vector specifically for bovine RNAi applications, we
identified and characterised a novel bovine U6 small nuclear RNA (snRNA) promoter from bovine
sequence data. This promoter is the putative bovine homologue of the human U6-8 snRNA
promoter, and features a number of functional sequence elements that are characteristic of these
types of pol. III promoters. A PCR based cloning strategy was used to incorporate this promoter
sequence into plasmid vectors along with shRNA sequences for RNAi. The promoter was then
used to express shRNAs, which resulted in the efficient knockdown of an exogenous reporter gene
and an endogenous bovine gene.
Conclusion: We have mined data from the bovine genome sequencing project to identify a
functional bovine U6 promoter and used the promoter sequence to construct a shRNA expression
vector. The use of this native bovine promoter in shRNA expression is an important component
of our future development of RNAi therapeutic and transgenic applications in bovine species.
Background
RNA interference (RNAi), a method of sequence specific
gene knockdown, has been used to analyse gene function
in plants, invertebrates, and more recently mammalian
cells [1-3]. The conserved RNAi pathway involves the
processing of double stranded RNA (dsRNA) duplexes
into 21–23 nucleotide (nt) molecules known as small
interfering RNAs (siRNA) to initiate gene knockdown [4-
6]. Since the discovery of RNAi in animals [7] the use of
long dsRNA in lower eukaryotes, especially in the model
organism Caenorhabditis elegans, has been used to deter-
mine gene function [8,9]. However, in mammalian
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viral defence mechanism initiated by interferon (IFN),
leading to non-specific translational shutdown and apop-
tosis [10-12].
This non-specific cellular activity can be circumvented by
the direct transfection of either chemically synthesised or
in vitro transcribed siRNAs of approximately 21 nt in
length into mammalian cells [1,13]. These short mole-
cules do not activate the IFN response, but can induce reli-
able and efficient transient knockdown of target genes
[14,15]. As a consequence, the development of DNA-
based vectors for expression of short hairpin RNA
(shRNA) molecules that are processed within the cell to
produce active siRNA molecules has progressed rapidly
[16-18]. Such DNA expression constructs have achieved
highly efficient gene knockdown without induction of the
IFN response.
DNA-based vectors offer some additional advantages over
chemical and in vitro synthesised siRNA. Vector construc-
tion is much less expensive compared to the chemical syn-
thesis of siRNA, selection of transfected cells is possible
via antibiotic selection and the option of inducible shRNA
transcription is also available. shRNA expression vectors
have been engineered using both viral (including retrovi-
ral [19], adenoviral [20] and lentiviral [21] vectors), and
plasmid systems [16-18]. These vectors often utilize pro-
moters from a small class of pol. III promoters [22,23] to
drive the expression of shRNA. Promoters of this type are
preferred because they naturally direct the synthesis of
small, highly abundant non-coding RNA transcripts, with
defined termination sequences consisting of 4–5 thymi-
dines (Ts) and have no requirement for downstream pro-
moter elements [22-24].
The human U6 snRNA promoter is the best studied type
III pol. III promoter. It has characteristic promoter ele-
ments known as the enhancer and core regions [25,26],
and is frequently used in RNAi expression vectors. A total
of nine full-length U6 loci have been identified from the
human genome [27]. These genes are dispersed through-
out the genome and five of these are potentially active,
including the previously described human U6 promoter,
now denoted U6-1. In the current study we describe the
characterisation of the bovine U6 snRNA promoter and its
expression of shRNA molecules in bovine cells. We used a
PCR based cloning strategy to construct a plasmid vector
that features the bovine U6 promoter to drive expression
of shRNA molecules directed at the exogenously expressed
Enhanced Green Fluorescent Protein (EGFP) and the
endogenous bovine gene, glyceraldehyde-3-phosphate
dehydrogenase (GAPDH).
Results and discussion
Characterisation of a bovine U6 promoter
A bovine BAC clone was identified from GenBank (Acces-
sion no. CC528275) that contained a 107 nt region that
shared 100% identity with the human U6 snRNA
sequence. A region directly upstream of this sequence also
shared significant homology with previously identified
human U6 promoter sequences. BLAT analysis revealed
that this BAC-clone shared the greatest sequence homol-
ogy with the human U6-8 promoter located on chromo-
some 14 [27]. The bovine BAC sequence contained
upstream promoter elements consistent with the human
U6 promoters and other human pol. III promoters [27-
30] (Fig. 1). These elements are also present in the mouse
U6 promoter used in the pSilencer 1.0-U6 siRNA Expres-
sion Vector (Ambion). The location and spacing of these
elements is similar for all human U6 promoters and their
requirement for pol. III activity is well documented [28-
30]. The presence of these elements in the bovine BAC-
clone sequence directly upstream of the full-length U6
snRNA suggested that this region may be an active bovine
promoter and could be used effectively to promote shRNA
expression.
shRNA expression vector construction
Using the predicted bovine U6 snRNA promoter sequence
as template, PCR based cloning strategies were used to
generate shRNA expression vectors targeting EGFP and
bovine GAPDH. A two-step PCR reaction was used to pro-
duce a vector targeting EGFP (pBovineU6-shEGFP) (Fig.
2A). One-step PCR reactions were used to produce an
shRNA expression vector targeting GAPDH (pBovineU6-
shGapdh), and a non-specific control shRNA
(pBovineU6-shScrambled) (Fig. 2B). In addition, using
the mouse U6 snRNA promoter sequence from pSilencer-
1.0 as template in one-step PCR reactions, shRNA expres-
sion vectors targeting EGFP (pMouseU6-shEGFP) and
bovine GAPDH (pMouseU6-shGapdh) were produced
(Fig. 2B).
In all constructs, the first nucleotide of the predicted
shRNA was a guanine (G) residue, corresponding to the
first nucleotide of the native U6 snRNA. An XbaI restric-
tion enzyme site was engineered downstream of the ter-
mination signal to allow screening for full-length shRNA
products inserted into pGEM-T Easy (Promega) which
lacks an XbaI site. All final shRNA expression constructs
consisted of either the full-length bovine or mouse U6
promoter, a shRNA sense sequence, a loop sequence, a
shRNA antisense sequence, a termination sequence and
an XbaI site.Page 2 of 9
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knockdown
To analyse the function of the bovine U6 promoter, the
level of EGFP expression in cells cotransfected with
pBovineU6-shEGFP and pEGFP-N1 (Clonetech) were
directly compared with EGFP expression in cells cotrans-
fected with pBovineU6-shScrambled and pEGFP-N1. An
indication of the bovine promoter efficiency was provided
by direct comparison to the level of EGFP knockdown by
the same shRNA molecule expressed from pMouseU6-
shEGFP. Prior to validation in bovine cells, both mouse
and bovine U6 promoter driven shRNA expression vectors
were first validated in Vero cells. As this cell line lacks the
interferon α, β and ω genes [31,32], a significant reduc-
tion in EGFP expression could be attributed to RNAi and
not the result of non-specific inhibition of protein trans-
lation characteristic of the IFN response triggered by
expressed exogenous dsRNA.
For each transfection condition, knockdown of EGFP in
Vero and MDBK cell lines was visualised by fluorescence
microscopy (Fig. 3A). Flow cytometry was used to deter-
mine the Mean Fluorescence Intensity (MFI) (Fig. 3B).
Results in both cell lines showed that cells transfected
with either pMouseU6-shEGFP or pBovineU6-shEGFP
exhibited large reductions in EGFP expression when com-
pared with cells transfected with pBovineU6-shScram-
bled.
To ensure that the observed reduction in EGFP expression
could be directly attributed to RNAi induced by expressed
shRNA, the transcription of these molecules was detected
in transfected cells. A radiolabelled RNA probe comple-
mentary in sequence to the EGFP shRNA sequence was
used in an RNAse protection assay to visualise these mol-
ecules. The mouse microRNA (miRNA) miR-16 probe
used as a loading control for each condition produced a
strong signal at the expected size for all samples (Fig. 3C).
The EGFP shRNA was detected only in those samples that
were transfected with either of the EGFP shRNA vectors
(Fig. 3C). There were no obvious differences in the
amount of shRNA produced by either the mouse or
bovine U6 promoters.
Activity of the bovine U6 promoter measured by GAPDH 
knockdown
To further validate the function of the bovine U6 pro-
moter for RNAi, shRNA expression vectors targeting the
Promoter element sequences of the bovine U6, human U6-8 and mouse U6 promotersFigure 1
Promoter element sequences of the bovine U6, human U6-8 and mouse U6 promoters. The distal promoter 
regions containing the SPH and OCT sequences and proximal promoter regions containing the PSE and TATA sequence ele-
ments are shown for each promoter. Matches to the consensus sequence delineated at the top of the SPH, OCT and PSE 
sequences are shown in upper case (SPH consensus is from Schaub et al., 1999 [28], PSE consensus is from Dahlberg et al., 
1988 [29] and OCT consensus is from Sturm et al. 1988 [30]). Note that the relative positions of the SPH and OCT elements 
are switched in the mouse promoter.Page 3 of 9
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active shRNA sequence was identified by testing three
siRNA sequences directed at this gene. Real-time PCR was
used to determine the relative amount of GAPDH in
MDBK cells transfected with the three siRNAs compared
to cells transfected with the scrambled sequence siRNA
control. A similar level of knockdown was achieved for
each of the bovine GAPDH siRNAs (Fig. 4A). The most
appropriate siRNA sequence, GAPDH #1, was selected for
use in construction of an shRNA vector as this sequence
did not contain any runs of T or A residues that may cause
premature termination of expressed shRNAs. This
sequence was used for both mouse and bovine U6 shRNA
vectors (pMouse-shGapdh and pBovine-shGapdh). Using
Real-time PCR, the relative amount of GAPDH in MDBK
cells transfected with pMouse-shGapdh and pBovine-
shGapdh was determined by comparison to cells trans-
fected with the irrelevant control plasmid pBovine-
shScrambled (Fig. 4B). Both vectors produced a very sim-
ilar level of GAPDH knockdown, although not as effective
Schematic representation of the PCR strategies used to produce shRNA expression vectorsFigure 2
Schematic representation of the PCR strategies used to produce shRNA expression vectors. (A): The two-step 
PCR method used to generate pBovineU6-shEGFP. The 1st PCR amplified the bovine U6 promoter, EGFP shRNA sense, loop, 
and 3 nt of EGFP shRNA antisense using primers LL16 and LL23. The 2nd PCR amplified the bovine U6 promoter and the 
remaining EGFP shRNA components including EGFP shRNA antisense, terminator and XbaI using primers LL16 and LL13. (B): 
The one-step PCR method used to generate pMouseU6-shEGFP, pBovineU6-shScrambled, pMouseU6-shGapdh and 
pBovineU6-shGapdh. PCR reactions used forward primers paired with single reverse primers comprising all shRNA compo-
nents. All final PCR products consisted of a mouse or bovine U6 promoter, shRNA sense, loop, shRNA antisense, termination 
sequence and XbaI site.
PCR Product
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Inhibition of EGFP expression and detection of expressed shRNA from bovine and mouse U6 promoters. (1) 
transfection free negative control (cells only); (2) transfection of pEGFP-N1; (3) cotransfection of pEGFP-N1 and pBovineU6-
shScrambled; (4) cotransfection of pEGFP-N1 and mouseU6-shEGFP; (5) cotransfection of pEGFP-N1 and pBovineU6-shEGFP. 
All transfections were performed in triplicate. (A): Typical fluorescence images of Vero and MDBK cells (Magnifications ×100). 
(B): Mean Fluorescence Intensity (MFI) of Vero and MDBK cells 72 hours post-transfection determined by flow cytometry. MFI 
of EGFP expressed as a percentage of the MFI of pEGFP-N1 + pBovineU6-shScrambled. (C): Detection of EGFP shRNAs in 
Vero cell extracts. Small RNAs were isolated from Vero cells and hybridised to a radiolabelled RNA probe identical in 
sequence to the EGFP shRNA (shEGFP). shEGFP was detected in lanes 4 and 5 only, and miR-16 was used as a loading control.Page 5 of 9
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fection efficiency for siRNAs is generally much greater
than that of large plasmid vectors.
Conclusion
We mined data from the bovine sequencing project and
identified a bovine U6 snRNA promoter that is the puta-
tive bovine homologue of the human U6-8 snRNA pro-
moter. This pol. III promoter sequence contains a number
of functional sequence elements that are characteristic of
this type of promoter and are essential for promoter func-
tion. The bovine U6 promoter sequence was used in the
construction of plasmid based shRNA expression vectors
pBovineU6-shEGFP and pBovineU6-shGapdh. These vec-
tors efficiently induced RNAi in MDBK and Vero cells
through production of shRNA molecules targeted at the
exogenously expressed reporter gene EGFP, and the
endogenous bovine gene GAPDH. The use of this pro-
moter sequence and the shRNA vector cloning strategy
described here will be advantageous in RNAi functional
genomic experiments in bovine cells. The characterisation
of this U6 promoter is an important step in the develop-
ment of novel bovine species specific RNAi based thera-
peutics. For ethical reasons it is essential to minimise the
introduction of non-bovine DNA sequences, conse-
quently this research could be of significance in the trans-
genic delivery of shRNA molecules in bovine species.
Methods
Bovine U6 promoter isolation
Oligonucleotides synthesized in this study are indicated
in Table 1. All the oligonucleotides were obtained from
GeneWorks Pty Ltd, except for LL91 which was obtained
from Proligo, and bovineGpdhPROBE from Applied Bio-
systems. The bovine BAC-end sequences deposited in the
Genome Survey Sequence (GSS) section of GenBank,
were compared with the U6 >95% identity sequence set
for Rfam models RF00026 http://www.sanger.ac.uk/Soft
ware/Rfam/index.shtml using BLAST with default param-
eters and a threshold e-value of 0.01 [33]. All hits detected
were scored against the appropriate Rfam covariance
model using the cmsearch function of INFERNAL [34].
Flanking repeat elements were identified using Repeat-
masker with the minus cow option http://www.repeat
masker.org/. Flanking sequences highly conserved
between Bos taurus and the human genome sequence were
identified using BLAT search (BLAST-like Alignment tool;
UC-Santa Cruz genome server [35]) from the UC-Santa
Cruz genome bioinformatics site http://genome.ucsc.edu/
cgi-bin/hgBlat.
A region of the bovine genome homologous to a bovine
BAC-end sequence (GenBank Accession no. CC528275)
predicted to contain a U6 snRNA promoter was amplified
from Bos taurus genomic DNA isolated from whole blood
using Wizard Genomic DNA Purification kit (Promega).
First round PCR amplification used forward primer LL16
with a reverse primer TD66 designed from the highly con-
served human U6 snRNA sequence. This PCR product was
then used as template for semi-nested PCR with LL16 and
antisense primer TD72 located 11 nt upstream of TD66 in
the U6 snRNA sequence. The second round PCR produced
a clean band of expected size (507 nt) that was gel purified
using QIAquick gel extraction kit (Qiagen), ligated into
pGEM-T Easy (Promega) as per the manufacturers instruc-
tions and sequenced.
Expression vector construction and shRNA target sites
A bovine U6 EGFP shRNA construct (pBovineU6-shE-
GFP) was produced using a two-step PCR approach. The
1st PCR paired LL16 with reverse primer LL23, comprising
Inhibition of bovine GAPDH expression in MDBK cellsFigure 4
Inhibition of bovine GAPDH expression in MDBK 
cells. The amount of GAPDH in MDBK cells was deter-
mined by Real-time PCR 48 hours post-transfection, 
expressed as a relative percentage compared to the amount 
of GAPDH in cells transfected with a scramble sequence 
siRNA. (A): Cells transfected with either siRNAs directed at 
bovine GAPDH or a scrambled sequence control siRNA. (B): 
MDBK cells transfected with pBovine-shScrambled, pMouse-
shGapdh and pBovine-shGapdh.Page 6 of 9
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sense, loop, and 3 nt EGFP shRNA antisense sequence.
This PCR product was used as template for semi-nested
PCR to produce the full-length shRNA template, using
LL16 and reverse primer LL13 with a short overlapping
region, comprising the 4nt EGFP shRNA sense, loop,
EGFP shRNA antisense, termination and XbaI.
A mouse U6 EGFP shRNA construct (pMouseU6-shEGFP)
was produced using one-step PCR with pSilencer 1.0-U6
siRNA Expression Vector (Ambion) as template. Universal
primer M13 Forward was paired with reverse primer
TD134, comprising the last 20 nt of the mouse promoter,
and all other EGFP shRNA components.
The EGFP shRNA sequence used for both bovine and
mouse vectors, had been shown previously to be effective
in silencing gene expression [36]. A bovine U6 EGFP
scrambled shRNA sequence (pBovineU6-shScrambled)
was produced using a sequence that showed no significant
homology to available monkey or bovine sequence data.
Forward primer LL16 was paired with reverse primer LL31
comprising the last 20 nt of the bovine U6 promoter, and
all other EGFP scrambled shRNA components.
Three siRNAs were designed based on the bovine GAPDH
sequence obtained from GeneBank (Accession no.
U85042) using the criteria described by Elbashir et al.,
2002 (37). Target sites for bovine GAPDH were; GAPDH
#1 (5'-AAGTTCAACGGCACAGTCAAG-3'); GAPDH #2
(5'-AACTTGACTGTGCCGTTGAAC-3'); GAPDH #3 (5'-
AAGGTCATCCATGACCACTTT-3'). To generate siRNAs,
oligonucleotides for sense and antisense-strands of each
siRNA together with T7 promoter sites were synthesized
and siRNAs were produced using the Ambion Silencer
siRNA construction kit (Ambion). Oligonucleotides used
for each were; GAPDH #1: LBG-as1 and LBG-as2; GAPDH
#2: LBG-as3 and LBG-s4; GAPDH #3: LBG-as5 and LBG-
s6 (Table 1).
A bovine U6 GAPDH shRNA expression construct
(pBovineU6-shGapdh) was generated using a one-step
PCR approach. LL16 was paired with LL05 which com-
prised the last 20 nt of the bovine U6 promoter and all
other GAPDH shRNA sequence components including
the GAPDH #1 siRNA sequence. Similarly, a mouse U6
GAPDH shRNA expression construct (pMouseU6-
shGapdh) was also generated. M13 universal primer was
paired with LL06, which also comprised the last 20 nt of
the mouse U6 promoter and all other GAPDH shRNA
components. All PCR products for shRNA expression con-
structs were ligated into pGEM-T Easy (Promega) and
sequenced.
Table 1: Synthesized oligonucleotides used in this study
Name Sequence
LL16 5'-CCAGCAAAGCAACCGATTC-3'
TD66 5'-GGCCATGCTAATCTTCTCTG-3'
TD72 5'-TTTTAGTATATGTGCTGCCG-3'
LL23 5'-ATCTCTCTTGAAGATGAACTTCAGGGTCAGCGGTTTGCCTTTCGTCCACGG-3'
LL13 5'-TCTAGATTCCAAAAAAGCTGACCCTGAAGTTCATCTCTCTTGAAGATG-3'
TD134 5'-TCTAGATTCCAAAAAAGCTGACCCTGAAGTTCATCTCTCTTGAAGATGAACTTCAGGG
TCAGCCAAACAAGGCTTTCTCCA-3'
LL31 5'-TCTAGATTCCAAAAAAAGCGCAGTGTTACTCCACTTCTCTTGAAAGTGGAGTAACACT
GCGCTGGTTTGCCTTTCGTCCACGG-3'
LBG-as1 5'-AAGTTCAACGGCACAGTCAAGCCTGTCTC-3'
LBG-s2 5'-AACTTGACTGTGCCGTTGAACCCTGTCTC-3'
LBG-as3 5'-AAGGTCATCCATGACCACTTTCCTGTCTC-3'
LBG-s4 5'-AAAAAGTGGTCATGGATGACCCCTGTCTC-3'
LBG-as5 5'-AAGCTCATTTCCTGGTACGACCCTGTCTC-3'
LBG-s6 5'-AAGTCGTACCAGGAAATGAGCCCTGTCTC-3'
LL05 5'- TCTAGATTCCAAAAAAGTTCAACGGCACAGTCAAGTCTCTTGAACTTGACTGTGCCGT
TGAACGGTTTGCCTTTCGTCCACGG-3'
LL06 5'-TCTAGATTCCAAAAAAGTTCAACGGCACAGTCAAGTCTCTTGAACTTGACTGTGCCGTT
GAACCAAACAAGGCTTTCTCCA-3'
BovineGpdhF 5'-AACGACCACTTTGTCAAGCTCAT-3'
BovineGpdhR 5'-TCCACCACCCTGTTGCTGTA-3'
BovineGpdhPROBE 5'-TCCTGGTACGACAATGA-3'
LL91 5'-RGRAURGRARARCUURCRARGRGRGURCRARGRC-3'
'r' prefix to G, A and C represents ribonucleotide, and U indicates ribo-uridine.Page 7 of 9
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MDBK (Madin Darby Bovine Kidney) and Vero (African
Green monkey kidney) cell lines were cultured in Eagle's
minimal essential medium (EMEM) medium containing
10% fetal calf serum (FCS), 2 mM glutamine, 10 mM
HEPES, supplemented with penicillin (100 U/ml) and
streptomycin (100 µg/ml). All cells were cultured in
humidified atmosphere containing 5% CO2 at 37°C. Vero
cells were grown to approximately 80% confluence on
either 24-well plates (Nunc) for Flow Cytometry, on 8-
well chamber slides (Lab-Tek) for fluorescence micros-
copy, or 6-well plates for shRNA detection. Cotransfection
with 500 ng for 24-well plates and chamber slides, or 2.5
µg for 6-well plates of plasmid DNA (shRNA plasmids
and/or pEGFP-N1 (Clonetech)) was carried out using
Lipofectamine 2000 (Invitrogen) according to the manu-
facturer's instructions. MDBK cells were grown to 80–90%
confluence in 75 cm2 flasks (Corning), harvested and
divided into aliquots of 1 × 106 cells per transfection.
Approximately 2.5 µg of each plasmid was transfected per
aliquot by electroporation using a Nucleofector (Amaxa)
according to the manufacturer's instructions. Electropo-
rated cells were dispensed into 8-well chamber slides for
fluorescence microscopy, 6-well plates (Nunc) for flow
cytometry or 24-well plates for Real-time PCR. Transfec-
tion of GAPDH siRNAs in MDBK cells grown to approxi-
mately 80% confluence on 24-well plates (Nunc) was
achieved using Lipofectamine 2000 with approximately
10 nM of each siRNA.
EGFP and GAPDH knockdown assays
EGFP expression was monitored at 72-hour post-transfec-
tion using fluorescence microscopy (Leica DMLB). Vero
and MDBK cells cultured in 8-well chamber slides were
washed with PBSA and mounting solution was applied
(9:1 glycerol: PBSA). Cells to be analysed by flow cytome-
try were trypsinized and washed in PBSA. Cells were then
resuspended in 200 µL 0.01% sodium azide and 2% FCS
in PBSA and analysed using a FACScalibur (Becton Dick-
inson) flow cytometer. Data analysis was performed using
CELLQuest software (Becton Dickinson).
Real-time RT-PCR reactions were carried out 48-hours
post-transfection. MDBK cells transfected with GAPDH
siRNAs and GAPDH shRNA vectors were harvest and
cDNA was produced using the Cells-to-cDNA II kit
(Ambion) using random hexamers. cDNA (2.5 µL) was
added to a 22.5 µL Real-time RT -PCR master mix contain-
ing 12.5 µL 2X TaqMan Universal PCR Master Mix
(Applied Biosystems), 2.5 µL (9 µM) each of sense primer
BovineGpdhF and antisense primer bovineGpdhR, 2.5 µL
(2.5 µM) of TaqMan MGB Probe (bovineGpdhPROBE)
(Applied Biosystems) and 2.5 µL RNase-free water (Table
1). For RNA normalization, an 18s rRNA PCR was per-
formed for each cDNA using the same PCR reagents
except for the primers and probes which were the Eukary-
otic 18srRNA Endogenous Control (Applied Biosystems).
Real-time PCR was carried out in a 7700 Sequence Detec-
tion Instrument (Applied Biosystems) using the following
thermal cycling profile: 95°C 1 min, followed by 35 cycles
of amplification (95°C 15s, 61°C 30s, 68°C 30s).
shRNA detection
Detection of EGFP shRNAs was carried by out using an
RNAse protection assay on extracts enriched for small
RNAs isolated from transfected Vero cells using a mirVana
miRNA Isolation Kit (Ambion). The RNA oligonucleotide
LL91 was end labelled with [gamma-32P] ATP using a mir-
Vana Probe & Marker Kit (Ambion) and hybridised to the
enriched RNAs using the mirVana miRNA Detection Kit
(Ambion). The RNA fragments were then separated by
electrophoresis on a 15% denaturing polyacrylamide/ 8 M
Urea gel and detected by autoradiography.
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